Alto Neuroscience (NYSE:ANRO) Reaches New 1-Year High – Here’s What Happened

Alto Neuroscience, Inc. (NYSE:ANRO) shares hit a new 52-week high on Monday . The stock traded as high as $23.66 and last traded at $23.03, with a volume of 109895 shares traded. The stock had previously closed at $22.26.

Key Headlines Impacting Alto Neuroscience

Here are the key news stories impacting Alto Neuroscience this week:

• Positive Sentiment: Alto secured approximately $120 million in a private placement (PIPE), strengthening near‑term cash runway to fund its clinical programs — a clear balance‑sheet positive for a clinical‑stage biotech. Read More.
• Positive Sentiment: Quarterly results: Alto reported ($0.45) EPS vs. consensus ($0.56), beating estimates and showing operating progress against expectations — a favorable signal for execution. Read More.
• Positive Sentiment: Chardan Capital reaffirmed a Buy rating and set a $30 price target, implying meaningful upside versus current levels and signaling continued analyst conviction in Alto’s pipeline. Read More.
• Neutral Sentiment: Wedbush raised its price target to $22 but kept a Neutral rating, effectively trimming the street’s short‑term upside view and providing mixed guidance to investors. Read More.
• Neutral Sentiment: Company released full‑year 2025 results and business highlights emphasizing pipeline progress and a stronger financial foundation entering 2026 — positive context but already priced against the financing and recent updates. Read More.
• Negative Sentiment: Potential dilution from the $120M PIPE — while the financing boosts cash, issuance of new securities can dilute existing shareholders and often weighs on the share price immediately after the announcement. Read More.
• Negative Sentiment: Market reaction: despite fundamentally positive items, mixed analyst positioning (Wedbush Neutral) plus dilution concerns have likely driven selling pressure and higher trading volume today. Read More.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. Chardan Capital reissued a “buy” rating and set a $30.00 price objective on shares of Alto Neuroscience in a report on Tuesday. BTIG Research increased their target price on Alto Neuroscience from $27.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday, February 17th. Wedbush lifted their price target on Alto Neuroscience from $13.00 to $22.00 and gave the company a “neutral” rating in a report on Tuesday. Jefferies Financial Group reissued a “buy” rating and issued a $35.00 price target on shares of Alto Neuroscience in a research report on Monday. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Alto Neuroscience in a research note on Monday, December 29th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Alto Neuroscience currently has a consensus rating of “Moderate Buy” and an average target price of $31.17.

Alto Neuroscience Stock Performance

The company has a debt-to-equity ratio of 0.20, a quick ratio of 15.42 and a current ratio of 15.42. The stock has a market cap of $699.29 million, a P/E ratio of -10.32 and a beta of 2.52. The firm’s 50 day moving average is $18.11 and its 200 day moving average is $13.35.

Alto Neuroscience (NYSE:ANRO) last announced its earnings results on Thursday, March 19th. The company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.11. Analysts anticipate that Alto Neuroscience, Inc. will post -2.54 EPS for the current year.

Institutional Trading of Alto Neuroscience

Institutional investors have recently made changes to their positions in the business. Vestal Point Capital LP grew its stake in Alto Neuroscience by 161.6% during the 4th quarter. Vestal Point Capital LP now owns 2,485,000 shares of the company’s stock worth $44,233,000 after buying an additional 1,535,000 shares during the last quarter. Commodore Capital LP purchased a new stake in Alto Neuroscience in the fourth quarter valued at about $32,453,000. Perceptive Advisors LLC boosted its holdings in Alto Neuroscience by 1,048.5% in the fourth quarter. Perceptive Advisors LLC now owns 1,784,393 shares of the company’s stock worth $31,762,000 after acquiring an additional 1,629,027 shares in the last quarter. Armistice Capital LLC boosted its holdings in Alto Neuroscience by 0.7% in the third quarter. Armistice Capital LLC now owns 1,636,000 shares of the company’s stock worth $6,577,000 after acquiring an additional 12,000 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Alto Neuroscience by 1.9% during the third quarter. Vanguard Group Inc. now owns 1,105,407 shares of the company’s stock worth $4,444,000 after acquiring an additional 20,702 shares during the last quarter.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.